Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Bets Moderna's Cancer Vaccines Can Prime Patients For Immunotherapy

Executive Summary

The companies will work together to develop personalized cancer vaccines against several tumor types, including an effort to pair a personalized vaccine with Keytruda.


Related Content

Finance Watch: Lots Of Money, Big And Small, Flowing Into Drug Development
Biopharma Unicorn Moderna Highlights Secretive Pipeline As Investors Await IPO
VC Roundup: Moderna Seeks Another Record-Breaking Raise; Arcus Emerges From Stealth Mode
Advaxis Advances Personalized Cancer Vaccines With Eye On Manufacturing Time, Cost
Moderna Signs Single Drug Deal With CF Expert Vertex For Up To $315m
VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs
AstraZeneca Ups Betting Ante On Moderna's Messenger RNA Technology
Merck moves into mRNA space with Moderna alliance
Moderna raises $450m; most ever for private biotech


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts